State Agencies
Sexual Violence Prevention Grant Request for Proposals
The goal of the Sexual Violence Prevention Grant Program is to support activities that stop sexual violence from occurring by making sure that all Minnesotans have a fair and just opportunity to achieve health and safety.4 This can be achieved by improving conditions in the environments where Minnesotans are born, live, learn, work, play, worship, and age.5 Program activities are required to focus on at least one of the following three priority areas:
• Strengthen economic supports for individuals and families
• Create protective environments
Ryan White HIV/AIDS Program Part D - Women, Infants, Children and Youth (WICY) Grant Supplemental Funding
The purpose of this additional funding is to increase access to high quality family-centered HIV health care services for low-income women, infants, children, and youth, commonly abbreviated as WICY.
Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) pre-trial feasibility and acceptability testing of services and service system research relevant to the prevention of substance use.
Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance.
Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed)
HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance.
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches.
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches.